Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of two drugs, piperacillin and tiotropium bromide. Piperacillin is a broad-spectrum beta-lactam antibiotic of the ureidopenicillin class, primarily used to treat serious infections caused by susceptible bacteria, including Pseudomonas aeruginosa. It acts by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins. Tiotropium bromide is a long-acting muscarinic antagonist (LAMA) bronchodilator used in the management of chronic obstructive pulmonary disease (COPD) and asthma. It works by blocking M3 muscarinic receptors in airway smooth muscle, leading to bronchodilation[1][3]. There are no known approved or marketed products that combine these two agents into a single formulation; their use together would be off-label or investigational.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on piperacillin + tiotropium bromide.